Dual-Site Transcranial Magnetic Stimulation of the Supplementary Motor Area and Cerebellum for the Treatment of Essential Tremor.
1 other identifier
interventional
36
1 country
1
Brief Summary
Essential tremor is a common movement disorder that causes involuntary shaking, mainly during voluntary actions such as writing or holding objects. Recent research suggests that essential tremor is not caused by a single brain area, but by abnormal activity within a network that includes the cerebellum and motor areas of the brain. However, most non-invasive brain stimulation studies to date have targeted only one brain region and have shown inconsistent clinical benefits. This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effects of a dual-site transcranial magnetic stimulation (rTMS) protocol targeting the supplementary motor area (SMA) and the cerebellum in patients with essential tremor that does not respond adequately to standard medications. The study is based on previous pilot data showing meaningful tremor reduction using combined stimulation of these two brain regions. Participants will receive five sessions of rTMS, consisting of low-frequency stimulation over the SMA followed by high-frequency stimulation over the cerebellum. The main hypothesis is that this combined approach will lead to an immediate and sustained improvement in action tremor of the dominant upper limb, measured up to four weeks after treatment. Secondary outcomes include quality of life, safety, side effects, and changes in brain excitability associated with tremor improvement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started Jan 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 7, 2026
CompletedFirst Posted
Study publicly available on registry
January 15, 2026
CompletedStudy Start
First participant enrolled
January 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2027
January 21, 2026
January 1, 2026
9 months
January 7, 2026
January 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Action Tremor Severity of the Dominant Upper Limb
Assessed using items 5 and 6 of the Fahn-Tolosa-Marin Tremor Rating Scale, evaluated by a blinded examiner.
baseline (pre-stimulation), at the end of the stimulation protocol, 4 weeks after the last session
Study Arms (2)
Dual-site rTMS over SMA (1 Hz, 110% RMT) and cerebellum (10 Hz, 90% RMT) for 5 days.
EXPERIMENTALSham stimulation over SMA and cerebellum using inactive coil with sound simulation for 5 days.
Sham
SHAM COMPARATORThe sham intervention replicates the anatomical targeting, sequence, session duration, and acoustic characteristics of the active dual-site rTMS protocol without delivering an effective magnetic field. An inactive coil is positioned over the same supplementary motor area and cerebellar targets, while sound simulation is used to mimic active stimulation, ensuring maintenance of blinding and comparability with the active intervention.
Interventions
This intervention consists of a sequential dual-site repetitive transcranial magnetic stimulation (rTMS) protocol targeting two interconnected nodes of the tremor network. Low-frequency stimulation (1 Hz) is first applied over the supplementary motor area at 110% of the resting motor threshold to modulate cortical motor drive, followed by high-frequency stimulation (10 Hz) over the cerebellar cortex at 90% of the resting motor threshold to modulate abnormal cerebellar output. Stimulation is delivered over five consecutive daily sessions using standardized anatomical localization and identical session duration across participants. Sham Intervention The sham intervention replicates the anatomical targeting, sequence, session duration, and acoustic characteristics of the active dual-site rTMS protocol without delivering an effective magnetic field. An inactive coil is positioned over the same supplementary motor area and cerebellar cortex
The sham intervention replicates the anatomical targeting, sequence, session duration, and acoustic characteristics of the active dual-site rTMS protocol without delivering an effective magnetic field. An inactive coil is positioned over the same supplementary motor area and cerebellar targets, while sound simulation is used to mimic active stimulation, ensuring maintenance of blinding and comparability with the active intervention.
Eligibility Criteria
You may qualify if:
- Male or female participants, aged 18 to 80 years; women of childbearing potential must not be pregnant.
- Diagnosis of Essential Tremor with a score greater than 2 on items 5 or 6 of the Fahn-Tolosa-Marin Tremor Rating Scale despite optimized medical therapy.
- Medication-refractory tremor, defined as prior use of both first-line medications (propranolol and primidone) at maximally tolerated doses without adequate tremor control.
- Ability to provide written informed consent in accordance with institutional policies.
- Ability to comply with all study procedures and follow-up assessments as defined by the study protocol.
You may not qualify if:
- Unstable or untreated psychiatric disorders.
- Inability to provide informed consent.
- Uncontrolled medical conditions, including but not limited to uncontrolled diabetes mellitus, hypertension, symptomatic pulmonary disease, or symptomatic cardiac disease.
- Concomitant participation in another investigational drug or device study.
- Pregnancy or breastfeeding.
- Presence of an implanted deep brain stimulation (DBS) system.
- History of epilepsy not adequately controlled, defined as seizure-free for less than 5 years.
- Presence of a cardiac pacemaker.
- Presence of metallic implants in any part of the body that are contraindicated for rTMS.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sao Paulo University
São Paulo, São Paulo, 05414-025, Brazil
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Masking Details
- Randomization will be performed by an independent researcher not involved in treatment delivery or outcome assessment. The randomization assignment will be communicated only to the investigator responsible for administering the transcranial magnetic stimulation (TMS). Clinical evaluations will be conducted by a separate investigator who is blinded to treatment allocation. Participants in the control group will receive sham stimulation using a sham coil positioned over the same scalp location as the active stimulation. The sham coil does not produce a magnetic field but is combined with a secondary coil placed near the participant to generate auditory stimulation, reproducing the sound characteristics of active TMS. Stimulation parameters and session duration will be identical to those used in the active group, in order to maintain participant blinding.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 7, 2026
First Posted
January 15, 2026
Study Start
January 15, 2026
Primary Completion (Estimated)
October 1, 2026
Study Completion (Estimated)
January 1, 2027
Last Updated
January 21, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Beginning 3 months and ending 2 years after the publication of results
- Access Criteria
- Requests for access to de-identified individual participant data will be considered for scientifically sound research purposes that are consistent with the objectives of the original study. Proposed analyses must not conflict with participant consent or institutional ethical approvals. Requests should include a brief research proposal outlining the study objectives, planned analyses, and statistical methods. All requests will be reviewed by the study investigators and, when required, by the institutional ethics committee. Data sharing will be contingent upon approval of the proposed analyses and execution of a data use agreement in accordance with institutional policies and applicable data protection regulations. Approved data will be shared in a de-identified format through secure data transfer methods.
De-identified individual participant data underlying the results reported in publications will be made available upon reasonable request to the corresponding author, following publication. Data sharing will be subject to approval by the institutional ethics committee and execution of a data use agreement, in accordance with applicable data protection regulations.